Table 3.
Variable | No. of Patients in Analysis* | Odds Ratio (95% confidence interval)† | |||
---|---|---|---|---|---|
For Each Variable | Remdesivir vs. ZMapp | MAb114 vs. ZMapp | REGN-EB3 vs. ZMapp | ||
Duration of symptoms | 615 | 1.11 (1.05–1.16) per day of symptoms‡ | 1.04 (0.66–1.64) | 0.49 (0.31–0.78) | 0.45 (0.28–0.73) |
Nucleoprotein Ct value | 620 | 0.66 (0.62–0.71) per 1 unit increase | 1.29 (0.71–2.34) | 0.39 (0.21–0.73) | 0.37 (0.20–0.68) |
Years of age | 623 | 1.00 (1.00–1.01) per 1 yr increase | 1.07 (0.68–1.66) | 0.52 (0.33–0.82) | 0.48 (0.31–0.77) |
Creatinine level§ | 507 | 1.43 (1.31–1.56) per 1 mg/dl increase | 0.93 (0.54–1.59) | 0.48 (0.27–0.84) | 0.38 (0.21–0.67) |
AST level§ | 380 | 1.15 (1.11–1.20) per 100 U/liter increase | 1.06 (0.54–2.05) | 0.31 (0.14–0.67) | 0.29 (0.14–0.63) |
ALT level§ | 511 | 1.43 (1.33–1.54) per 100 U/liter increase | 0.95 (0.54–1.68) | 0.37 (0.20–0.69) | 0.36 (0.20–0.66) |
Patient-reported vaccination§ | 620 | 0.37 (0.24–0.55) yes vs. no | 1.06 (0.67–1.68) | 0.48 (0.30–0.77) | 0.44 (0.28–0.71) |
Model estimates include data from patients who were enrolled after the REGN-EB3 group was added. The number of patients in the analysis reflects the number enrolled after the REGN-EB3 group was added for whom data were available for each variable.
Each row shows the odds ratios derived from a multivariate logistic-regression model that included the variable listed plus the four treatment groups.
The variable reflects each additional day of symptoms before admission to the treatment center.
Because of its clinical significance, the variable was added after the statistical analysis plan was finalized but before analysis of the data.